Media centre

Vernalis to Present at Cowen and Company 7th Annual Global Health Care Conference

2 November 2006

WINNERSH, U.K., November 2, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer, will participate in the Cowen and Company 7th Annual Global Health Care Conference to be held November 7-8, 2006 at the Landmark Hotel in London.  Mr. Sturge is scheduled to present an overview of the Company’s business activities and product pipeline at 16:50 GMT on Wednesday, November 8, 2006.

 

Investors may access a live webcast of the presentation at www.vernalis.com under the Investor Relations tab. The presentation will be archived for 3 months.

 

About Vernalis

Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a US commercial operation to promote Apokyn® and co-promote Frova® alongside its North American licensing partner, Endo Pharmaceuticals, progressing the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit www.vernalis.com.

-- ends --

Enquiries:

Vernalis plc

+44 (0) 118 977 3133

Simon Sturge, Chief Executive Officer

 

Tony Weir, Chief Financial Officer

 

Julia Wilson, Head of Corporate Communications

 

 

 

Brunswick Group

+44 (0) 20 7404 5959

Jon Coles

 

Justine McIlroy

 

 

 

Lazar Partners Ltd

 

Gregory Gin

212-867-1762

 

 

 

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch